Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autologous tumour infiltrating lymphocytes - Shanghai Juncell Therapeutics

Next Previous
Drug Profile

Autologous tumour infiltrating lymphocytes - Shanghai Juncell Therapeutics

Alternative Names: GC 101 TIL injection; TILS - Shanghai Gencells Therapeutics; Tumor infiltrating lymphocytes - Shanghai Gencells Therapeutics

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Juncell Therapeutics
  • Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I Non-small cell lung cancer; Solid tumours
  • No development reported Breast cancer; Gastrointestinal stromal tumours; Glioma

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for phase-I development in Breast-cancer(In the elderly, Metastatic disease, Second-line therapy or greater, In adults) in China (IV)
  • 20 Dec 2024 Phase-II clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (NCT06703398)
  • 25 Nov 2024 Shanghai Juncell Therapeutics plans the phase II MIZAR-003 trial for Melanoma (Late-stage disease, Inoperable/Unresectable, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV, Injection), in December 2024 (NCT06703398)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top